Trials now focus on the discovery of tumor-associated antigens (i.e., E75-specific CD8 + T cells that lysed HER-2/neu expressing tumor cells) to create vaccines that further stimulate the patient’s own immune system [25]. The gene discussed is ERBB2; the disease is neoplasm.